Loading...
Autolus Therapeutics plc
AUTL•NASDAQ
Healthcare
Biotechnology
$1.59
$-0.12(-7.02%)
U.S. Market opens in 7h 47mAutolus Therapeutics plc (AUTL) AI-Powered Stock Analysis
See how Autolus Therapeutics plc scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerAutolus Therapeutics plc (AUTL) Stock Overall Grade
Autolus Therapeutics plc’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Autolus Therapeutics plc's overall stock rating.
Forecast
C+Score
52/100Financial Growth
A+Score
90/100Fundamental Growth
CScore
48/100Key Ratios
CScore
45/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
99/100Analyst Consensus
B+Score
75/100Autolus Therapeutics plc (AUTL) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (90/100, A+) and Fundamental Growth (48/100, C) highlight its stability, while Key Ratios (45/100, C) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), it shows competitive strength. Analyst Consensus (75/100,B+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Autolus Therapeutics plc stock grade, including financials, comparisons, and forecasts.